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Proteomic cell surface phenotyping of differentiating acute
myeloid leukemia cells
Abstract
Immunophenotyping by flow cytometry or immunohistochemistry is a clinical standard procedure for
diagnosis, classification, and monitoring of hematologic malignancies. Antibody-based cell surface
phenotyping is commonly limited to cell surface proteins for which specific antibodies are available and
the number of parallel measurements is limited. The resulting limited knowledge about cell surface
protein markers hampers early clinical diagnosis and subclassification of hematologic malignancies.
Here, we describe the mass spectrometry based phenotyping of 2 all-trans retinoic acid treated acute
myeloid leukemia model systems at an unprecedented level to a depth of more than 500 membrane
proteins, including 137 bona fide cell surface exposed CD proteins. This extensive view of the leukemia
surface proteome was achieved by developing and applying new implementations of the Cell Surface
Capturing (CSC) technology. Bioinformatic and hierarchical cluster analysis showed that the applied
strategy reliably revealed known differentiation-induced abundance changes of cell surface proteins in
HL60 and NB4 cells and it also identified cell surface proteins with very little prior information. The
extensive and quantitative analysis of the cell surface protein landscape from a systems biology
perspective will be most useful in the clinic for the improved subclassification of hematologic
malignancies and the identification of new drug targets.
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Abstract 
Immunophenotyping by flow cytometry or immunohistochemistry is a clinical standard procedure for 
diagnosis, classification, and monitoring of hematological malignancies. Antibody-based cell surface 
phenotyping is commonly limited to cell surface proteins for which specific antibodies are available 
and the number of parallel measurements is limited. The resulting limited knowledge about cell 
surface protein markers hampers early clinical diagnosis and sub-classification of hematological 
malignancies. Here, we describe the mass spectrometry based phenotyping of two all-trans retinoic 
acid treated acute myeloid leukemia model systems at an unprecedented level to a depth of more than 
500 membrane proteins, including 137 bona fide cell surface exposed CD proteins. This extensive 
view of the leukemia surface proteome was achieved by developing and applying new 
implementations of the Cell Surface Capturing (CSC) technology. Bioinformatic and hierarchical 
cluster analysis showed that the applied strategy reliably revealed known differentiation-induced 
abundance changes of cell surface proteins in HL60 and NB4 cells and it also identified cell surface 
proteins with very little prior information. The extensive and quantitative analysis of the cell surface 
protein landscape from a systems biology perspective will be most useful in the clinic for the improved 
sub-classification of hematological malignancies and the identification of new drug targets. 
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Introduction 
Current diagnosis of hematological malignancies relies on a combination of the immunophenotype, 
morphology, cytochemistry, and karyotype according to the WHO classification1 and the previously 
used FAB classification.2,3 The current WHO classification divides neoplasms according to their 
lineage into myeloid neoplasms, lymphoid neoplasms, histiocytic neoplasms, and mast cell disorders. 
As a neoplasm of the myeloid lineage, acute myeloid leukemia (AML) is one of the most frequently 
diagnosed types of leukemia in adults. Acute promyelocytic leukemia (APL) is a distinct subtype of 
AML and it seems to be the most malignant form of AML characterized by a life threatening 
coagulopathy.4 APL is cytogenetically characterized by a specific reciprocal translocation t(15;17), 
which results in the fusion between the promyelocytic leukemia gene and the retinoic acid receptor α 
gene. All-trans retinoic acid (ATRA) binds to retinoic acid receptors and it induces differentiation of 
APL cells into granulocyte-like cells. Since the 1980s, ATRA has been successfully applied in the 
clinic and the combination of ATRA and anthracycline-based chemotherapy is highly effective to 
induce complete remission in APL patients.5 However, approximately 25% of APL patients treated 
with ATRA suffer from the differentiation syndrome.6 The differentiation syndrome is characterized 
by increased leukocyte transmigration, for which cell surface proteins play a crucial role.7 
Cell surface protein markers are commonly used in clinical immunohistochemistry and flow cytometry 
to immunophenotype hematological malignancies, such as AML. The process of immunophenotyping 
malignant cells implies the availability of affinity reagents, such as antibody-based probes. However, 
for the detection of cell surface exposed proteins, only a limited number of specific anti-CD antibodies 
are available for consistent, clinical-grade immunophenotyping. The CD nomenclature for cell surface 
molecules was devised in 1984 by the Human Leukocyte Differentiation Antigen (HLDA) Workshop 
in order to better characterize and study cell surface molecules. The HLDA Workshops have up to now 
assigned 350 CD numbers to cell surface molecules, against which two independent antibodies are 
available.8 For example, in order to distinguish myeloid from lymphoid neoplasms, monoclonal 
antibodies against the pan-myeloid cell surface markers CD13, CD33, and CD65 are used.9 Although a 
few hundred anti-CD antibodies are available, less than 50 anti-CD antibodies are used to 
immunophenotype hematological neoplasms by flow cytometry.10 
Antibody arrays are a promising technology towards a more complete immunophenotype of cells, 
since they allow the concurrent determination of 130 different surface antigens.11 However, all 
antibody-based technologies are limited to the number of available antibodies and therefore they are 
not suitable for the discovery of new cell surface markers. Mainly due to the lack of suitable affinity 
reagents, the cell surface proteome of most cells, including AML cells, is not well known. Several 
thousand proteins of the human proteome are predicted to contain a transmembrane segment12 and 
many of these transmembrane proteins are expected to be exposed on the cell surface of different cell 
types, influencing the communication potential of these cell types with their particular 
microenvironments. 
The currently limited knowledge about the cell surface protein phenotype of malignant cells hampers 
the precise clinical disease sub-classification on the protein level, the predictive management of the 
disease, and the selection of therapeutic target proteins.10 In order to predict and efficiently treat 
hematological malignancies, it is necessary to understand cellular behavior on the protein level and an 
essential step is to gain a qualitative and quantitative overview of the cell surface proteome. To reach 
these goals, techniques supporting an extensive analysis of the cell surface proteome are required. 
Mass spectrometry (MS) based proteomics enables the multiplexed identification and quantification of 
peptides in a discovery-driven analysis of the proteome.13 The analysis of the cell surface proteome by 
MS is hampered by factors, such as the hydrophobicity of transmembrane proteins and the low relative 
abundance of cell surface proteins compared to intracellular proteins.14 We recently circumvented 
most of these issues by developing the MS-based CSC technology,15 which enables the reproducible 
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identification and quantification of cell surface proteins.16 The CSC technology is based on hydrazide 
chemistry and it enables the specific enrichment of glycopeptides through the biotinylation of glycans 
of cell surface proteins. 
Here, we applied a range of complementary CSC technology variants selecting overlapping segments 
of the cell surface proteome for the multiplexed identification and relative quantification of AML cell 
surface proteins upon ATRA stimulation. By using HL60 and NB4 cells as differentiation model 
systems, we identified more than 500 membrane proteins, including 137 CD annotated proteins and 
detected distinct molecular phenotypes of drug-induced differentiation processes independent of 
antibodies. 
Materials and methods 
Cell culture 
HL60 and NB4 cells were kindly provided by Dr. Juerg Gertsch (Institute of Pharmaceutical Sciences, 
ETH Zurich, Switzerland) and Dr. Udo Doebbeling (Department of Dermatology, University Hospital 
Zurich, Switzerland), respectively. HL60 and NB4 cells were cultured in RPMI 1640 (10% FCS, 100 
units/ ml penicillin, and 100 µg/ ml streptomycin; Sigma-Aldrich, Buchs, Switzerland). For ATRA 
stimulation experiments, cells were cultured for at least six cell doublings in RPMI 1640 containing 
10% dialyzed FCS (BioConcept, Allschwil, Switzerland) and either L-arginine and L-lysine (light 
medium; Sigma-Aldrich) or L-[13C6,15N4]arginine and L-[13C6,15N2]lysine (heavy medium; Sigma-
Aldrich). HL60 and NB4 cells were stimulated by adding 1 µM ATRA (Sigma-Aldrich) for 4 days. 
Three independent ATRA stimulation experiments were carried out for each AML cell line and the 
Cys-Glyco-CSC, Glyco-CSC, and Lys-CSC technology variant were applied in each experiment. In 
two experiments of each cell line, cells cultured in heavy medium were stimulated with ATRA and 
cells cultured in light medium were unstimulated. In one experiment of each cell line, cells cultured in 
light medium were stimulated with ATRA and cells cultured in heavy medium were unstimulated. 
CSC technology and sample preparation 
Equal cell numbers (~108 cells) of ATRA stimulated and unstimulated cells that were cultured in light 
and heavy medium, respectively, were used for one CSC experiment. By using variants of the original 
CSC technology, three partially overlapping cell surface sub-proteomes consisting of glycoproteins, 
cysteine containing glycoproteins, and lysine containing proteins, respectively, were selectively 
isolated and analyzed by MS. 
Cys-Glyco-CSC/ Glyco-CSC: The protocol for the isolation of cysteine containing peptides and N-
linked glycopeptides was adapted from the initial CSC protocol.15 Briefly, cells were treated for 15 
min at 4 °C in the dark with 2 mM sodium meta-periodate (Pierce, Rockford, IL, USA) in PBS pH 6.5. 
Afterwards, cells were washed and incubated with 6.5 mM biocytin hydrazide (Biotium, Hayward, 
CA, USA) in PBS pH 6.5 for 60 min to biotinylate oxidized carbohydrates of cell surface 
glycoproteins. Then, cells were washed again and incubated on ice in hypotonic lysis buffer (10 mM 
Tris pH 7.5, 0.5 mM MgCl2, and 10 mM iodoacetamide) for 10 min. Cells were homogenized with 
forty strokes using a Dounce homogenizer. Afterwards, cell debris and nuclei were removed by 
centrifugation at 1,700 g for 7 min and the supernatant was centrifuged again in an ultracentrifuge at 
35,000 r.p.m (~150,000 g) for 1 h to generate a membrane pellet. The membrane pellet was solubilized 
in 400 µl digestion buffer (100 mM ammonium bicarbonate, 1 mM iodoacetamide, 1 mM 2,2'-
thiodiethanol, and 0.1% RapiGest; Waters, Milford, MA, USA) by indirect sonication with a 
VialTweeter (Hielscher, Teltow, Germany). Proteins were digested overnight with trypsin in a 
protease:protein ratio of 1:100. Iodoacetamide was added to the digestion buffer to preserve protein 
disulfide bridges and 2,2'-thiodiethanol was added to prevent overalkylation of peptides.17 After 
protein digestion, the peptide mixture was heated at 95 °C for 10 min to inactivate trypsin and then 
biotinylated glycopeptides were bound to Streptavidin Plus UltraLink Resin (SA beads; Pierce). After 
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extensive washing, cysteine containing peptides, which were bound via a disulfide bridge to the 
biotinylated glycopeptides, were eluted form the SA beads by incubation with elution buffer (100 mM 
ammonium bicarbonate, 10 mM TCEP, and 1 mM DTT) for 1h at room temperature (Cys-Glyco-
CSC). Afterwards, SA beads were washed again and in a second elution step N-linked glycopeptides 
were enzymatically released from the SA beads overnight by PNGase F (Glyco-CSC). Produced free 
thiols of cysteine containing peptides were alkylated with iodoacetamide. Peptides were desalted on 
Ultra MicroTIP Columns (The Nest Group, Southborough, MA, USA) and dried in a SpeedVac 
concentrator. Finally, peptides were solubilized in LC-MS grade water containing 0.1% formic acid 
and 5% acetonitrile. 
Lys-CSC: The Lys-CSC protocol differed from the above described Cys-Glyco-CSC/ Glyco-CSC 
protocol only in few steps: biotinylation of cell surface proteins was carried out in HL60 cells by 
incubation with 2 mM sulfosuccinimidyl-2-(biotinamido)-ethyl-1, 3’-dithiopropionate (sulfo-NHS-SS-
biotin; Pierce) and in NB4 cells by incubation with 2 mM sulfosuccinimidyl-6-(biotinamido) 
hexanoate (sulfo-NHS-LC-biotin; Pierce) for 30 min at 4 °C on a MACSmix tube rotator (Miltenyi 
Biotec, Bergisch Gladbach, Germany), a sucrose gradient centrifugation step was used for the 
enrichment of membranes as described elsewhere,18 and N-glycosylated proteins were deglycosylated 
by PNGase F for 2 h at room temperature before protein digestion. The samples generated by CSC 
technology variants were stored frozen and analyzed individually. 
MS analysis 
Each peptide sample generated from HL60 cells was analyzed twice on an Eksigent Nano LC system 
(Eksigent Technologies, Dublin, CA, USA) connected to a hybrid linear ion trap LTQ Orbitrap 
(Thermo Scientific, Waltham, MA, USA), which was equipped with a nanoelectrospray ion source 
(Thermo Scientific). Peptide separation was carried out on a RP-HPLC column (75 µm inner diameter 
and 10 cm length) packed in-house with C18 resin (Magic C18 AQ 3 µm; Michrom Bioresources, 
Auburn, CA, USA) using a linear gradient from 90% solvent A (water, 0.2% formic acid, and 1% 
acetonitrile) and 10% solvent B (water, 0.2% formic acid, and 80% acetonitrile) to 65% solvent A and 
35% solvent B over 39 min at a flow rate of 0.2 µl/ min. The data acquisition mode was set to acquire 
one high resolution MS scan in the ICR cell followed by three collision induced dissociation MS/MS 
scans in the linear ion trap. For a high resolution MS scan, 2x106 ions were accumulated over a 
maximum time of 400 ms and the FWHM resolution was set to 60,000 (at m/z 300). Only MS signals 
exceeding 500 ion counts triggered a MS/MS attempt and 104 ions were acquired for a MS/MS scan 
over a maximum time of 200 ms. The normalized collision energy was set to 35%. Singly charged ions 
were excluded from triggering MS/MS scans. Each peptide sample generated from NB4 cells was 
analyzed similarly (for details see supplemental Materials). 
MS data analysis 
Raw data files from the MS instruments were converted with ReAdW into mzXML files19 and 
mzXML files were searched with Sorcerer™-SEQUEST®20 (for details see supplemental Materials) 
against a concatenated protein database combining the human protein database of the 
UniProtKB/Swiss-Prot Protein Knowledgebase (version 56.9), the reversed sequences of all proteins, 
and common contaminants (41,104 protein entries). Statistical analysis of each search result for each 
LC-MS analysis was performed using the Trans-Proteomic Pipeline TPP21 v4.0 JETSTREAM rev 2 
including PeptideProphet22 and ProteinProphet.23 The ProteinProphet probability score was set to 0.9, 
which resulted in an average protein false discovery rate of less than 1% for all search results 
estimated by ProteinProphet. Proteins, which were identified with only single peptide identifications in 
the whole data set, were excluded from subsequent analyses. If peptide identifications led to an 
indistinguishable group of proteins, the alphabetically first UniProtKB/Swiss-Prot AC number was 
used for subsequent analyses and the remaining protein identifiers of the protein group were listed in 
supplemental tables. For the final data set, a protein false discovery rate of less than 1% and a peptide 
false discovery rate of less than 1% were estimated by the MAYU software.24 CD numbers were 
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mapped to UniProtKB/Swiss-Prot IDs according to the UniProtKB/Swiss-Prot Protein Knowledgebase 
cross-reference table (version 57.0). Transmembrane helices of proteins were predicted with two 
algorithms, the TMHMM algorithm25 (version 2.0) and the Phobius algorithm.26 Protein identifications 
were denoted as membrane proteins, if at least one transmembrane helix algorithm predicted one or 
more transmembrane helices for the protein sequences. Furthermore, proteins, which contained a lipid 
moiety-binding region according to the UniProtKB/Swiss-Prot Protein Knowledgebase, were also 
denoted as membrane proteins. 
To quantify protein abundance changes between ATRA stimulated and unstimulated AML cells, 
identical Sorcerer™-SEQUEST® search criteria and TPP settings were applied as above, with the 
exception of two required tryptic termini per peptide. Proteins, which were not identified in the 
database search with at least one tryptic terminus per peptide and which were only identified with 
single peptide identifications in the database search with two tryptic termini per peptide, were 
excluded from subsequent analyses. Protein ratios of ATRA stimulated to unstimulated cells were 
determined for each LC-MS analysis by applying the XPRESS software27 and protein ratios were 
normalized by the mean protein ratio of each experiment. The mean protein ratio of an experiment was 
determined by a Gaussian curve fit to the histogram of all log10 protein ratios of the experiment. For 
the comparison of ATRA stimulated cells to unstimulated cells, the average log2 XPRESS protein 
ratios were calculated over the two LC-MS analyses of each CSC technology variant of each 
experiment, then the average values were calculated over all CSC technology variants of each 
experiment, and then the average values were calculated over all three experiments for each AML cell 
line. The sequence coverage of identified proteins was determined with the Protein Coverage 
Summarizer (version 1.2.3365), which was downloaded from the website of the Biological MS Data 
and Software Distribution Center of the Pacific Northwest National Laboratory (Richland, WA, USA). 
Molecular functions of identified proteins were assigned by the PANTHER database (version 6.1.1) 
based on the alphabetically first UniProtKB/Swiss-Prot AC number. Hierarchical cluster analysis was 
carried out with the Spotfire DecisionSite 9.1.1 software (TIBCO Software Inc., Palo Alto, CA, USA) 
based on average log2 XPRESS protein ratios (log2 protein ratios) of quantified membrane proteins. 
For the hierarchical cluster analysis, log2 protein ratios above 3 or below -3 were trimmed to 3 and -3, 
respectively. Membrane proteins were excluded from the hierarchical cluster analysis, if the trimmed 
log2 protein ratios differed by more than 2 between HL60 and NB4 cells. Unweighted pair-group 
method with arithmetic mean was chosen for clustering method and Euclidean distance for similarity 
measure.  
Flow cytometry 
CD proteins in HL60 and NB4 cells were analyzed by direct immunofluorescence. First, cells were 
washed with PBS and then incubated for 30 min at 4 °C in PBS containing 10% human serum in order 
to block Fc-receptors. After subsequent washing, 400,000 cells were incubated for 20 min at 4 °C in 
25 µl of a 1:12.5 dilution of anti-CD11b-FITC (Sigma-Aldrich), anti-CD54-PE (BD Biosciences, 
Allschwil, Switzerland), anti-CD55-FITC (Abcam, Cambridge, UK) or anti-CD71-FITC (BD 
Biosciences) antibody. For each antibody staining, 10,000 cells were analyzed on a FACSCalibur 
System (BD Biosciences) and FlowJo7 (Tree Star, Ashland, OR, USA) was used for data analysis. 
ATRA stimulated AML cells showed consistently in both fluorescence channels (FL-1 and FL-2) a 
slightly increased fluorescence intensity (FI) compared with unstimulated cells. Therefore, the 
geometric mean FI values of the antibody stainings of ATRA stimulated cells were corrected by 
subtracting the difference between the geometric mean FI values of unstained, ATRA stimulated 
control cells and unstained, unstimulated control cells. For each antibody staining in each experiment, 
the log2 ratio of the geometric mean FI values of ATRA stimulated to unstimulated cells was 
calculated and then the average value over all experiments was calculated for each antibody staining 
for each cell line. 
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Results 
Cellular differentiation of AML cells 
HL60 and NB4 cells are well characterized in vitro model systems for AML and myeloid 
differentiation.28,29 Only NB4 cells carry the specific reciprocal translocation t(15;17), the hallmark of 
APL. Although HL60 and NB4 cells carry different genetic aberrations, ATRA induces differentiation 
of both AML cell lines into morphologically mature granulocytes.29,30 In order to relatively quantify 
protein abundance changes of ATRA stimulated compared to unstimulated AML cells by MS, both 
cell lines were cultured in SILAC medium containing isotope labeled amino acids.31 AML cells were 
stimulated with 1 µM ATRA for 4 days and cellular differentiation was controlled by flow cytometric 
analysis of CD11b.29,32 
Complementary CSC technology variants 
We adapted and expanded the original CSC glycopeptide selection technology15 to increase the 
sensitivity and the range of captured peptides. Here, we utilized complementary CSC technology 
variants (Figure 1) for the first time to identify and quantify the cell surface proteome of AML cells 
after ATRA stimulation. Equal cell numbers (~108 cells) of ATRA stimulated and unstimulated AML 
cells were combined and cell surface exposed proteins were chemoselectively biotin-tagged either by 
the Cys-Glyco-CSC/ Glyco-CSC or the Lys-CSC approach. With the Cys-Glyco-CSC and Glyco-CSC 
technology variant, N-linked glycopeptides (Glyco-CSC) and cysteine containing peptides (Cys-
Glyco-CSC) bound via disulfide bridges to cysteine containing glycopeptides were concurrently 
identified. Furthermore, we used amine-reactive biotin derivatives to tag cell surface proteins (Lys-
CSC).33 After tagging of cell surface proteins, cell membranes were isolated and proteins were 
digested with trypsin. Biotinylated peptides were then isolated by affinity chromatography with 
streptavidin beads. Cysteine containing peptides bound via disulfide bridges to biotinylated peptides 
were eluted from the streptavidin beads by chemical reduction. These cysteine containing peptides 
were coined ‘piggyback’ peptides, since their enrichment was mediated by the biotinylated peptides. 
Biotinylated N-glycosylated peptides were enzymatically released from streptavidin beads by PNGase 
F. Finally, peptides were analyzed by LC-MS. 
Overall, these LC-MS measurements led to the identification of more than 500 membrane proteins, 
including 137 CD annotated cell surface proteins (Table 1 and S1-3). Nearly half of the identified 
membrane proteins were shared between both AML cell lines (Figure 2A). Furthermore, 188 and 235 
membrane proteins were identified in HL60 and NB4 cells, respectively, with only one CSC 
technology variant showing that the three enrichment strategies were complementary in order to 
extensively analyze the cell surface proteome (Figure 2B). In addition, if distinct peptides of a protein 
were identified with different CSC technology variants, confidence of correct protein identification 
was further increased. Since different amine-reactive biotin derivatives were used (for details see 
“Materials and methods”), it was not possible to directly compare the distribution of identified 
membrane proteins in the two AML cell lines. However, similar functional protein classes were found 
in the PANTHER database34 for the identified membrane proteins in both AML cell lines (Figure 2C; 
Table S4), including receptor proteins, cell adhesion proteins, signaling proteins, and transporters. 
Furthermore, identified peptides showed a high specificity of up to over 90% in LC-MS analyses 
(Table S5). Specific peptides for the Cys-Glyco-CSC and Lys-CSC technology variant contained 
cysteine residues. Specific peptides for the Glyco-CSC technology variant contained deamidated 
glycosylation motives (NXS/T   DXS/T; N is asparagine, X is any amino acid except proline, S/T is 
either serine or threonine, and D is aspartic acid) due to the PNGase F treatment.  
Multiplexed proteomic CD phenotyping 
Immunophenotyping of hematological malignancies has traditionally depended on well characterized 
monoclonal antibodies and it is commonly restricted to few antibodies. In contrast, the data generated 
with MS-based CSC technology variants contained 137 CD proteins and therefore phenotyped ATRA 
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stimulated AML cells at an unprecedented level (Figure 3). Identified CD proteins included the 
hematopoietic cell surface marker CD45 as well as pan-myeloid markers such as CD13 and CD33. 
Well known granulocyte differentiation markers such as CD11b, CD11c, CD35, and CD66a were also 
identified.35 More than 75% of the CD proteins were identified with more than 10 assigned spectra per 
CD protein in at least one AML cell line, demonstrating the robustness of cell surface phenotyping 
with the CSC technology.  
CSC technology versus flow cytometry 
To compare the accuracy of MS-based quantification of protein abundance changes by the CSC 
technology with that obtained by flow cytometry, we analyzed CD11b, CD54, CD55, and CD71 by 
flow cytometry in ATRA stimulated and unstimulated AML cells (Figure 4). In the flow cytometric 
analysis, the average log2 FI ratios of CD proteins were calculated with the geometric mean FI values 
of ATRA stimulated and unstimulated cells (Figure 4B). The flow cytometric analysis indicated a 
significant increase in CD11b, CD54, and CD55 protein abundances and a sharp decrease of CD71 
protein abundances in both AML cell lines after ATRA stimulation. In the MS-based CSC analysis, 
protein abundance changes were quantified by applying the XPRESS software27 to the generated MS 
datasets (Table S6-7). Based on peptide identifications, the XPRESS software isolated 
chromatographic elution profiles of the unlabeled and the heavy isotope labeled peptides, respectively, 
and determined the area of each peptide peak. XPRESS protein ratios were then calculated by the 
geometric mean of the ratios of corresponding peptide peak areas. In agreement with the flow 
cytometric analysis, log2 protein ratios of ATRA stimulated to unstimulated AML cells indicated a 
significant increase in CD11b, CD54, and CD55 protein abundances and a sharp decrease of CD71 
protein abundances in both AML cell lines after ATRA stimulation (Figure 4C).  
ATRA regulated membrane proteins 
In order to identify commonly regulated membrane proteins after ATRA induced cellular 
differentiation of AML cells, hierarchical cluster analysis was applied to the log2 protein ratios of 
identified membrane proteins in both AML cell lines (Figure 5; Table S8). The hierarchical cluster 
analysis was restricted to the 165 membrane proteins that fulfilled the following criteria: firstly, the 
proteins had to be identified in both AML cell lines; secondly, the proteins had to be quantified with a 
similar log2 protein ratio of ATRA stimulated to unstimulated cells in both cell lines (for details see 
“Materials and methods”). Three functional protein clusters were defined. Protein cluster number one 
(Figure 5B) contained membrane proteins, which showed decreased protein abundances in both AML 
cell lines after ATRA stimulation. The ATRA induced stop of cell proliferation of AML cells is known 
to be characterized by decreased transferrin receptor (CD71, TFR1) abundance.30 Consistent with this 
expectation and as described above, decreased protein abundances of CD71 were detected after ATRA 
stimulation by the MS-based CSC technology in both AML cell lines. In addition, several other 
membrane proteins were detected that showed decreased protein abundances after ATRA stimulation, 
such as the zinc transporter (S39AE), the amino acid transporter (SATT), and plexin D1 (PLXD1). 
Protein cluster number two contained 139 membrane proteins, which showed either no change or a 
differential regulation of protein abundances in the two AML cell lines. Finally, protein cluster number 
three contained membrane proteins, which showed increased protein abundances in both AML cell 
lines after ATRA stimulation (Figure 5C). Proteins in cluster number three included well known 
markers of granulocytic differentiation, such as CD66a, CD300a, CD11c, CD11b, CD35 and 
CD55.35,36 EMR3 and EMR1, which were described as granulocyte markers,37,38 were also identified 
with highly increased protein abundances after ATRA stimulation. Furthermore, cell surface proteins 
were identified, which are known to show increased protein abundances after ATRA stimulation, such 
as CD36, CD38, CD54, and CY24B.39-43 Interestingly, cluster number three also included proteins 
with very little prior information in the literature about their functional role in AML cells, such as 
GPR97 and TTYH3. 
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These results show that major common cell surface proteome changes in HL60 and NB4 cells upon 
ATRA induced differentiation were captured with the CSC technology. In addition to commonly 
regulated membrane proteins after ATRA stimulation, 30 quantified membrane proteins showed in the 
two AML cell lines differences between the log2 protein ratios of more than 2 (Table S7) and 274 
membrane proteins were only identified in one cell line (Figure 2A; Table S2). Since only NB4 cells 
carry the specific reciprocal translocation t(15;17), HL60 and NB4 cells belong to different FAB 
categories, FAB-M2 and FAB-M3, respectively. Thus, the detected differences between the two AML 
cell lines in membrane protein regulation after ATRA stimulation were most likely due to different 
genetic backgrounds and different genetic aberrations between the cell lines.29,30 
Discussion 
Cell surface proteins are readily accessible and well suited as diagnostic and therapeutic targets. 
Extensive classification of malignancies based on cell surface proteins is often hampered by the lack of 
known disease specific cell surface markers and the lack of well characterized antibodies against these 
markers. Here, we present extensive cell surface molecular phenotypes and an extensive analysis of 
cell surface protein dynamics in ATRA stimulated AML cells by using a MS-based strategy termed 
CSC technology. By enriching peptides from extracellular domains of cell surface proteins, the CSC 
technology allowed a multiplexed identification and quantification of hundreds of membrane proteins 
in AML cells. We demonstrate that complementary CSC technology variants were able to efficiently 
enrich for glycopeptides and cysteine containing ‘piggyback’ peptides. The Glyco-CSC technology 
variant not only identified N-linked glycopeptides but also indicated locations of glycosylation sites of 
identified peptides. Through deamidated NXS/T glycosylation motives of identified peptides, we 
determined 775 glycosylation sites of 311 distinct membrane proteins in AML cells (Table S3). The 
Cys-Glyco-CSC and Lys-CSC technology variant enriched for peptides that were disulfide-linked to 
glycopeptides and lysine-containing peptides, respectively (Figure 1). These disulfide-linked 
‘piggyback’ peptides frequently increased sequence coverage of identified glycoproteins and 
‘piggyback’ peptides also enabled identification of membrane proteins, which were not identified by 
MS through glycopeptides. Thus, the combination of all three CSC technology variants was beneficial 
to increase the number of identified membrane proteins (Figure 2B) and additional valuable 
information about cell surface proteins was obtained, such as locations of N-glycosylation sites. 
ATRA regulated membrane proteins 
Changes of membrane protein abundances in AML cells after ATRA stimulation were revealed by 
MS-based protein quantification. The two most prominent biological processes, which are mediated by 
ATRA stimulation in AML cells, are differentiation into granulocyte-like cells and stop of cell 
proliferation. Many of the identified membrane proteins, which showed changed protein abundances in 
the two AML cell lines after ATRA stimulation, were assigned to these two biological processes. 
These proteins included CD11b, CD11c, CD35, CD36, CD38, CD54, CD55, CD66a, CD300a, 
CY24B, and CD71.30,35,36,39-43 Interestingly, all four members of the epidermal growth factor-like 
seven-transmembrane (EGF-TM7) domain family, which includes CD97, EMR1, EMR2, and EMR3, 
were identified in both AML cell lines. Only small changes in protein abundances were detected in the 
two AML cell lines after ATRA stimulation for CD97 and EMR2, which are both known to be 
important for granulocyte migration.44,45 In contrast, the two functionally less well characterized EGF-
TM7 receptors, EMR1 and EMR3,37,38 were detected with highly increased protein abundances in both 
AML cell lines after ATRA stimulation by the CSC technology (Figure 5C). Furthermore, protein 
abundances of two members of the plexin family were detected to be differently regulated by ATRA. 
Decreased protein abundances of plexin D1 (PLXD1) but increased protein abundances of CD232 
(PLXC1) were detected in both AML cell lines after ATRA stimulation. Plexins were originally 
identified in the nervous system and they are known for their crucial role in axon guidance. In recent 
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years, it has been shown that plexins also play an important role in the immune system.46 Levels of 
mRNA coding for plexin C1 were shown to be decreased in blast cells of AML patients.47 This finding 
correlates with our results of decreased plexin C1 protein abundances in unstimulated compared to 
ATRA stimulated AML cells. ATRA induced abundance changes of proteins that may be important 
for granulocyte migration, such as EGF-TM7 receptors or plexins, are interesting in connection with 
increased leukocyte transmigration in the differentiation syndrome in ATRA treated APL patients. 
Furthermore, the proteins LT4R1 and IGSF2 were detected to be less abundant in unstimulated 
compared to ATRA stimulated AML cells. Interestingly, levels of mRNA coding for these two 
proteins were recently described to be decreased in chronic myeloid leukemia in blast crisis.48 Protein 
abundances of TTYH3 and GPR97 were also detected to be increased in AML cells after ATRA 
stimulation, but the functions of these proteins in AML cells have not yet been clearly described and 
need to be analyzed in more detail. Overall, many here identified ATRA regulated membrane proteins 
in AML cells have been described before in the literature, indicating the robustness and reliability of 
phenotyping cells with the CSC technology. In addition, we identified numerous functionally 
uncharacterized and also putative proteins in AML cells, showing the value of the CSC technology for 
protein marker discovery. 
Targeted MS-based phenotyping 
The presented AML surface proteome illustrates the complexity of functional cell surface protein 
classes, which determine to a large extent the interaction capacities of AML cells with their 
microenvironment. Probably not only the classes of proteins present at the cell surface at a certain time 
are important but also their relative quantities between each other and their absolute abundances in the 
cell are critical to regulate cellular functions. Sensitive and accurate quantification of selected proteins, 
in order to determine protein copy numbers per cell, can now be achieved by MS workflows through 
the development of peptide-specific Selected Reaction Monitoring (SRM) assays, which are based on 
the measurement of selected fragment ions of peptides.49 The data generated in the here described 
experiments enable now the selection of such peptide fragment ions for targeted SRM-based strategies. 
The combination of the CSC technology with quantitative SRM assays will significantly contribute to 
the comprehensive and systematic validation of abundance changes of selected cell surface proteins. 
Such technologies that enable the systematic comparison of cell surface phenotypes of different cell 
states have the potential to create new perspectives for improved classification and targeted treatment 
of hematological malignancies. 
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Tables 
Table 1. Number of identified membrane proteins in HL60 and NB4 cells 
Cell line Membrane proteins CD proteins 
HL60 385 119 
NB4 417 113 
HL60 & NB4 538 137 
Figure legends 
Figure 1. CSC technology. Unstimulated and ATRA stimulated NB4 cells were cultured in light 
medium (LM) and heavy medium (HM), respectively. Equal cell numbers of unstimulated and ATRA 
stimulated NB4 cells were combined and cell surface proteins were biotinylated on living cells either 
by the Cys-Glyco-CSC/ Glyco-CSC protocol or the Lys-CSC protocol. After membrane preparation 
and protein digestion, biotinylated peptides were isolated by streptavidin affinity chromatography. 
’Piggyback’ peptides were bound via disulfide bridges to biotinylated peptides on streptavidin beads, 
since protein disulfide bridges had been protected during cell lysis and protein digestion. In the Cys-
Glyco-CSC and Lys-CSC protocol, ’piggyback’ peptides were eluted from streptavidin beads by 
chemical reduction. In the Glyco-CSC protocol, peptides with N-glycosylation were enzymatically 
released from streptavidin beads by PNGase F. HL60 cells were processed analogously except for the 
Lys-CSC protein biotinylation (for details see “Materials and methods”). 
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Figure 2. Mapping the cell surface proteome through complementary CSC technology variants. 
A) Overlap of identified membrane proteins in AML cells. B) Area-proportional Venn diagrams50 
showing overlapping membrane protein identifications with complementary CSC technology variants 
in HL60 cells and NB4 cells, respectively. C) PANTHER molecular functions of identified membrane 
proteins in AML cells. 
 
Figure 3. Extensive CD phenotyping of AML cells. Overview on 137 CD proteins identified in 
AML cells by the MS-based CSC technology. The inner color code of the squares visualizes the 
number of assigned spectra per CD protein for HL60 cells (upper squares) and NB4 cells (lower 
squares), respectively.  
 
Figure 4. Flow cytometric analysis and MS-based CSC analysis of CD protein abundance 
changes in AML cells after ATRA stimulation. A) Representative flow cytometric analysis of CD 
proteins in unstimulated (blue line) and ATRA stimulated (red line) AML cells. Unstimulated and 
ATRA stimulated control AML cells are shown in plain dark grey and light grey, respectively. B) 
Results of the flow cytometric analysis are shown as the average log2 ratios of the geometric mean FI 
signals of ATRA stimulated to unstimulated AML cells (n=3). Error bars represent standard 
deviations. C) Results of the MS-based CSC analysis are shown as the average log2 protein ratios of 
ATRA stimulated to unstimulated AML cells (n=3). Error bars represent standard deviations. 
 
Figure 5. Membrane protein abundance changes in AML cells after ATRA stimulation. A) 
Hierarchical cluster analysis of log2 protein ratios of 165 membrane proteins that were identified in 
both AML cell lines by the MS-based CSC technology. Each row represents the abundance changes of 
one membrane protein after ATRA stimulation and each column represents one AML cell line. Red 
indicates increased protein abundance, while green indicates decreased protein abundance after ATRA 
stimulation. B) Protein cluster number one contained membrane proteins, which showed decreased 
protein abundances in both AML cell lines after ATRA stimulation. Names of proteins are shown next 
to the heat map and if applicable CD numbers are included. Numbers in brackets are the number of 
peptide identifications used for quantification of the protein in HL60 (first number) and in NB4 cells 
(second number), respectively. C) Protein cluster number three contained membrane proteins, which 
showed increased protein abundances in both AML cell lines after ATRA stimulation. 
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